A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

NCT04532268 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Non-hodgkin Lymphoma,B Cell

Interventions

DRUG: Humanized CD19 CAR-T cells

Sponsor

Zhejiang University

Collaborators

[object Object]